187 related articles for article (PubMed ID: 31758038)
1. Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance.
Inder S; Bates M; Ni Labhrai N; McDermott N; Schneider J; Erdmann G; Jamerson T; Belle VA; Prina-Mello A; Thirion P; Manecksha PR; Cormican D; Finn S; Lynch T; Marignol L
Sci Rep; 2019 Nov; 9(1):17325. PubMed ID: 31758038
[TBL] [Abstract][Full Text] [Related]
2. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
Young A; Berry R; Holloway AF; Blackburn NB; Dickinson JL; Skala M; Phillips JL; Brettingham-Moore KH
BMC Cancer; 2014 Nov; 14():808. PubMed ID: 25369795
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
Chen X; Chen F; Ren Y; Weng G; Keng PC; Chen Y; Lee SO
Prostate; 2019 Sep; 79(12):1386-1398. PubMed ID: 31334877
[TBL] [Abstract][Full Text] [Related]
4. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
6. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.
Seifert M; Peitzsch C; Gorodetska I; Börner C; Klink B; Dubrovska A
PLoS Comput Biol; 2019 Nov; 15(11):e1007460. PubMed ID: 31682594
[TBL] [Abstract][Full Text] [Related]
7. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
8. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy.
Wu CT; Chen WC; Liao SK; Hsu CL; Lee KD; Chen MF
Endocr Relat Cancer; 2007 Sep; 14(3):633-43. PubMed ID: 17914094
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.
Todorovic V; Prevc A; Zakelj MN; Savarin M; Brozic A; Groselj B; Strojan P; Cemazar M; Sersa G
Radiat Oncol; 2019 Nov; 14(1):214. PubMed ID: 31775835
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.
Kita K; Shiota M; Tanaka M; Otsuka A; Matsumoto M; Kato M; Tamada S; Iwao H; Miura K; Nakatani T; Tomita S
Cancer Sci; 2017 Sep; 108(9):1820-1827. PubMed ID: 28691182
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
[TBL] [Abstract][Full Text] [Related]
13. Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.
McDermott N; Meunier A; Mooney B; Nortey G; Hernandez C; Hurley S; Lynam-Lennon N; Barsoom SH; Bowman KJ; Marples B; Jones GD; Marignol L
Sci Rep; 2016 Oct; 6():34796. PubMed ID: 27703211
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
Stark TW; Hensley PJ; Spear A; Pu H; Strup SS; Kyprianou N
Prostate; 2017 Dec; 77(16):1583-1591. PubMed ID: 29063620
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism.
Xu S; Wang T; Song W; Jiang T; Zhang F; Yin Y; Jiang SW; Wu K; Yu Z; Wang C; Chen K
Sci Rep; 2015 Aug; 5():13528. PubMed ID: 26314494
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
18. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
Fan Y; Fan H; Quan Z; Wu X
Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
[TBL] [Abstract][Full Text] [Related]
19. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.
Mahajan K; Coppola D; Rawal B; Chen YA; Lawrence HR; Engelman RW; Lawrence NJ; Mahajan NP
J Biol Chem; 2012 Jun; 287(26):22112-22. PubMed ID: 22566699
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor.
Guseva NV; Rokhlin OW; Bair TB; Glover RB; Cohen MB
Oncotarget; 2012 Feb; 3(2):183-94. PubMed ID: 22383394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
